Should You Buy Krystal Biotech Inc (KRYS) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/30
KRYS is a **buy right now**. Price is in a broader uptrend (bullish moving-average stack) and has pulled back toward a nearby support zone, creating a reasonable entry for an impatient buyer. Fundamentals and Wall Street sentiment are strongly positive (multiple recent target raises and Buy ratings), and the company is showing strong profitability momentum.
**Intellectia Proprietary Trading Signals**
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock today.
Technical Analysis
Trend is still **bullish** on moving averages (SMA_5 > SMA_20 > SMA_200), but momentum has softened short-term.
- MACD histogram: **-1.666** and negatively expanding → bearish/weakening momentum (near-term pullback risk).
- RSI(6): **~54** → neutral, not overbought.
- Levels: Pivot **282.40** (current **278.44** is below pivot), Support **273.43** then **267.89**; Resistance **291.37** then **296.91**.
Interpretation: structurally bullish trend with a near-term dip; buying near current levels is essentially buying a pullback above key support.
Analyst Ratings and Price Target Trends
Street trend is **decisively improving**: multiple firms raised price targets and reiterated/initiated Buys in January 2026.
- Clear Street: PT raised to **$338** (Buy) on Vyjuvek growth + pipeline appreciation (notably KB801/NK).
- BofA: PT raised to **$318** (Buy), highlighting NK data as a major share driver.
- Citi: upgraded to **Buy** with **$309** PT; other firms (TD Cowen, H.C. Wainwright) also lifted targets after positive CF data.
Wall Street pros: accelerating commercial execution (Vyjuvek), high margins, and meaningful pipeline optionality.
Wall Street cons: key pipeline readouts (e.g., NK data timing/results) are major “binary” catalysts that can swing sentiment.
Influential/politician flows: **No recent congress trading data**; hedge fund and insider activity noted as **neutral**.
Wall Street analysts forecast KRYS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRYS is 229.25 USD with a low forecast of 198 USD and a high forecast of 278 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast KRYS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRYS is 229.25 USD with a low forecast of 198 USD and a high forecast of 278 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 272.910
Current: 272.910
